Ultrasensitive Virion Immunoassay Platform with Dual-Modality Based on a Multifunctional Aggregation-Induced Emission Luminogen — Ling‐Hong Xiong (2018) | RDL Network
Ultrasensitive Virion Immunoassay Platform with Dual-Modality Based on a Multifunctional Aggregation-Induced Emission Luminogen
Article 2018 en
Authors
LX
Ling‐Hong Xiong
XH
Xuewen He
ZZ
Zheng Zhao
Abstract
1 min read
Sensitive and accurate detection of highly contagious virus is urgently demanded for disease diagnosis and treatment. Herein, based on a multifunctional aggregation-induced emission luminogen (AIEgen), a dual-modality readout immunoassay platform for ultrasensitive detection of viruses has been successfully demonstrated. The platform is relied on virions immuno-bridged enzymatic hydrolysis of AIEgen, accompanying with the in situ formation of highly emissive AIE aggregates and shelling of silver on gold nanoparticles. As a result, robust turn-on fluorescence and naked-eye discernible plasmonic colorimetry composed dual-signal is achieved. By further taking advantage of effective immunomagnetic enrichment, EV71 virions, as an example, can be specifically detected with a limit of detection down to 1.4 copies/μL under fluorescence modality. Additionally, semiquantitative discerning of EV71 virions is realized in a broad range from 1.3 × 10<sup>3</sup> to 2.5 × 10<sup>6</sup> copies/μL with the naked eye. Most importantly, EV71 virions in 24 real clinical samples are successfully diagnosed with 100% accuracy. Comparing to the gold standard polymerase chain reaction (PCR) assay, our immunoassay platform do not need complicated sample pretreatment and expensive instruments. This dual-modality strategy builds a good capability for both colorimetry based convenient preliminary screening and fluorescence based accurate diagnosis of suspect infections in virus-stricken areas.
Chengcheng Zhou, Meijuan Jiang, Jian Du, Haotian Bai, Guo‐Gang Shan, Ryan T. K. Kwok, Joe H. C. Chau, Jun Zhang, Jacky W. Y. Lam, Peng Huang, Ben Zhong Tang
Discussion(0)
No comments yet. Be the first to comment.